Skip to main content
Top
Published in: European Journal of Clinical Microbiology & Infectious Diseases 5/2017

01-05-2017 | Original Article

Demonstration of the herd effect in adults after the implementation of pneumococcal vaccination with PCV13 in children

Authors: C. Hays, Q. Vermee, A. Agathine, A. Dupuis, E. Varon, C. Poyart, M.-C. Ploy, J. Raymond, and the ORP Ile de France Ouest

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 5/2017

Login to get access

Abstract

The purpose of this investigation was to describe the evolution of serotypes and antibiotic susceptibility of Streptococcus pneumoniae strains isolated from both adults and children from the same population area with invasive pneumococcal disease (IPD) or acute otitis media (AOM), 5 years after the introduction of the 13-valent pneumococcal conjugate vaccine (PCV13). From 2009 to 2015, 839 strains of S. pneumoniae strains were collected (481 from adults and 358 from children). Serotyping by latex antisera and molecular methods was performed. Antimicrobial susceptibility was tested. Compared to 2009, the total number of strains isolated in 2015 decreased in children (263 vs. 53, respectively) and in adults (220 vs. 131, respectively). Serotype coverage of PCV13 for IPD decreased significantly in adults from 67.7% (149/220) to 25.2% (33/131) and in children from 75.1% (61/81) to 18.5% (5/27). Especially, serotypes 1, 7F and 19A decreased significantly in children, while serotypes 7F and 19A decreased significantly in adults. PCV13 serotypes involved in AOM decreased significantly over the 5-year period, from 85.7% (156/182) to 38.5% (10/26), and were more susceptible to penicillin, amoxicillin and cefotaxime, p < 0.05. Serotypes 8, 9N and 10A seemed to emerge in adults, whereas any serotype prevalence was observed in children. Between 2009 and 2015, the introduction of PCV13 has resulted in a significant decrease of the number of S. pneumoniae strains isolated from IPD in children as in adults. It highlights a strong herd effect of vaccination in adults.
Literature
1.
go back to reference Bogaert D, De Groot R, Hermans PWM (2004) Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect Dis 4:144–154CrossRefPubMed Bogaert D, De Groot R, Hermans PWM (2004) Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect Dis 4:144–154CrossRefPubMed
2.
go back to reference De Lencastre H, Tomasz A (2002) From ecological reservoir to disease: the nasopharynx, day-care centres and drug-resistant clones of Streptococcus pneumoniae. J Antimicrob Chemother 50:75–81CrossRefPubMed De Lencastre H, Tomasz A (2002) From ecological reservoir to disease: the nasopharynx, day-care centres and drug-resistant clones of Streptococcus pneumoniae. J Antimicrob Chemother 50:75–81CrossRefPubMed
3.
go back to reference AlonsoDeVelasco E, Verheul AF, Verhoef J, Snippe H (1995) Streptococcus pneumoniae: virulence factors, pathogenesis, and vaccines. Microbiol Rev 59:591–603PubMedPubMedCentral AlonsoDeVelasco E, Verheul AF, Verhoef J, Snippe H (1995) Streptococcus pneumoniae: virulence factors, pathogenesis, and vaccines. Microbiol Rev 59:591–603PubMedPubMedCentral
4.
go back to reference Hausdorff WP, Feikin DR, Klugman KP (2005) Epidemiological differences among pneumococcal serotypes. Lancet Infect Dis 5:83–93CrossRefPubMed Hausdorff WP, Feikin DR, Klugman KP (2005) Epidemiological differences among pneumococcal serotypes. Lancet Infect Dis 5:83–93CrossRefPubMed
5.
go back to reference Lepoutre A, Varon E, Georges S, Dorléans F, Janoir C, Gutmann L, Lévy-Bruhl D; Microbiologists of Epibac; ORP Networks (2015) Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001–2012. Vaccine 33:359–66CrossRefPubMed Lepoutre A, Varon E, Georges S, Dorléans F, Janoir C, Gutmann L, Lévy-Bruhl D; Microbiologists of Epibac; ORP Networks (2015) Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001–2012. Vaccine 33:359–66CrossRefPubMed
6.
go back to reference Lepoutre A, Varon E, Georges S, Gutmann L, Lévy-Bruhl D (2008) Impact of infant pneumococcal vaccination on invasive pneumococcal diseases in France, 2001–2006. Euro Surveill 13(35): pii: 18962 Lepoutre A, Varon E, Georges S, Gutmann L, Lévy-Bruhl D (2008) Impact of infant pneumococcal vaccination on invasive pneumococcal diseases in France, 2001–2006. Euro Surveill 13(35): pii: 18962
7.
go back to reference Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, Reingold A, Cieslak PR, Pilishvili T, Jackson D, Facklam RR, Jorgensen JH, Schuchat A; Active Bacterial Core Surveillance of the Emerging Infections Program Network (2003) Decline in invasive pneumococcal disease after the introduction of protein–polysaccharide conjugate vaccine. N Engl J Med 348:1737–1746CrossRefPubMed Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, Reingold A, Cieslak PR, Pilishvili T, Jackson D, Facklam RR, Jorgensen JH, Schuchat A; Active Bacterial Core Surveillance of the Emerging Infections Program Network (2003) Decline in invasive pneumococcal disease after the introduction of protein–polysaccharide conjugate vaccine. N Engl J Med 348:1737–1746CrossRefPubMed
8.
go back to reference Black S, Shinefield H, Baxter B, Austrian R, Elvin L, Hansen J, Lewis E, Fireman B (2006) Impact of the use of heptavalent pneumococcal conjugate vaccine on disease epidemiology in children and adults. Vaccine 24:S79–S80 Black S, Shinefield H, Baxter B, Austrian R, Elvin L, Hansen J, Lewis E, Fireman B (2006) Impact of the use of heptavalent pneumococcal conjugate vaccine on disease epidemiology in children and adults. Vaccine 24:S79–S80
9.
go back to reference Lexau CA, Lynfield R, Danila R, Pilishvili T, Facklam R, Farley MM, Harrison LH, Schaffner W, Reingold A, Bennett NM, Hadler J, Cieslak PR, Whitney CG; Active Bacterial Core Surveillance Team (2005) Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 294:2043–2051CrossRefPubMed Lexau CA, Lynfield R, Danila R, Pilishvili T, Facklam R, Farley MM, Harrison LH, Schaffner W, Reingold A, Bennett NM, Hadler J, Cieslak PR, Whitney CG; Active Bacterial Core Surveillance Team (2005) Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 294:2043–2051CrossRefPubMed
10.
go back to reference Haber M, Barskey A, Baughman W, Barker L, Whitney CG, Shaw KM, Orenstein W, Stephens DS (2007) Herd immunity and pneumococcal conjugate vaccine: a quantitative model. Vaccine 25:5390–5398CrossRefPubMed Haber M, Barskey A, Baughman W, Barker L, Whitney CG, Shaw KM, Orenstein W, Stephens DS (2007) Herd immunity and pneumococcal conjugate vaccine: a quantitative model. Vaccine 25:5390–5398CrossRefPubMed
11.
go back to reference Dortet L, Ploy MC, Poyart C, Raymond J; ORP Ile de France Ouest (2009) Emergence of Streptococcus pneumoniae of serotype 19A in France: molecular capsular serotyping, antimicrobial susceptibilities, and epidemiology. Diagn Microbiol Infect Dis 65:49–57CrossRefPubMed Dortet L, Ploy MC, Poyart C, Raymond J; ORP Ile de France Ouest (2009) Emergence of Streptococcus pneumoniae of serotype 19A in France: molecular capsular serotyping, antimicrobial susceptibilities, and epidemiology. Diagn Microbiol Infect Dis 65:49–57CrossRefPubMed
12.
go back to reference Grall N, Hurmic O, Al Nakib M, Longo M, Poyart C, Ploy MC, Varon E, Raymond J; ORP Ile de France Ouest (2011) Epidemiology of Streptococcus pneumoniae in France before introduction of the PCV-13 vaccine. Eur J Clin Microbiol Infect Dis 30:1511–1519CrossRefPubMed Grall N, Hurmic O, Al Nakib M, Longo M, Poyart C, Ploy MC, Varon E, Raymond J; ORP Ile de France Ouest (2011) Epidemiology of Streptococcus pneumoniae in France before introduction of the PCV-13 vaccine. Eur J Clin Microbiol Infect Dis 30:1511–1519CrossRefPubMed
13.
go back to reference Hurmic O, Grall N, Al Nakib M, Poyart C, Grondin S, Ploy MC, Varon E, Raymond J; ORP Ile de France-Ouest Network (2014) Evidence of a clonal expansion of Streptococcus pneumoniae serotype 19A in adults as in children assessed by the DiversiLab® system. Eur J Clin Microbiol Infect Dis 33:2067–2073 Hurmic O, Grall N, Al Nakib M, Poyart C, Grondin S, Ploy MC, Varon E, Raymond J; ORP Ile de France-Ouest Network (2014) Evidence of a clonal expansion of Streptococcus pneumoniae serotype 19A in adults as in children assessed by the DiversiLab® system. Eur J Clin Microbiol Infect Dis 33:2067–2073
14.
go back to reference Whitney CG, Pilishvili T, Farley MM, Schaffner W, Craig AS, Lynfield R, Nyquist AC, Gershman KA, Vazquez M, Bennett NM, Reingold A, Thomas A, Glode MP, Zell ER, Jorgensen JH, Beall B, Schuchat A (2006) Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case–control study. Lancet 368:1495–1502CrossRefPubMed Whitney CG, Pilishvili T, Farley MM, Schaffner W, Craig AS, Lynfield R, Nyquist AC, Gershman KA, Vazquez M, Bennett NM, Reingold A, Thomas A, Glode MP, Zell ER, Jorgensen JH, Beall B, Schuchat A (2006) Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case–control study. Lancet 368:1495–1502CrossRefPubMed
15.
go back to reference Singleton RJ, Hennessy TW, Bulkow LR, Hammitt LL, Zulz T, Hurlburt DA, Butler JC, Rudolph K, Parkinson A (2007) Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA 297:1784–1792CrossRefPubMed Singleton RJ, Hennessy TW, Bulkow LR, Hammitt LL, Zulz T, Hurlburt DA, Butler JC, Rudolph K, Parkinson A (2007) Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA 297:1784–1792CrossRefPubMed
16.
go back to reference Hsu KK, Pelton SI (2003) Heptavalent pneumococcal conjugate vaccine: current and future impact. Expert Rev Vaccines 2:619–631CrossRefPubMed Hsu KK, Pelton SI (2003) Heptavalent pneumococcal conjugate vaccine: current and future impact. Expert Rev Vaccines 2:619–631CrossRefPubMed
17.
go back to reference Hammitt LL, Bruden DL, Butler JC, Baggett HC, Hurlburt DA, Reasonover A, Hennessy TW (2006) Indirect effect of conjugate vaccine on adult carriage of Streptococcus pneumoniae: an explanation of trends in invasive pneumococcal disease. J Infect Dis 193:1487–1494CrossRefPubMed Hammitt LL, Bruden DL, Butler JC, Baggett HC, Hurlburt DA, Reasonover A, Hennessy TW (2006) Indirect effect of conjugate vaccine on adult carriage of Streptococcus pneumoniae: an explanation of trends in invasive pneumococcal disease. J Infect Dis 193:1487–1494CrossRefPubMed
18.
go back to reference Beall B, McEllistrem MC, Gertz RE Jr, Wedel S, Boxrud DJ, Gonzalez AL, Medina MJ, Pai R, Thompson TA, Harrison LH, McGee L, Whitney CG; Active Bacterial Core Surveillance Team (2006) Pre- and postvaccination clonal compositions of invasive pneumococcal serotypes for isolates collected in the United States in 1999, 2001, and 2002. J Clin Microbiol 44:999–1017CrossRefPubMedPubMedCentral Beall B, McEllistrem MC, Gertz RE Jr, Wedel S, Boxrud DJ, Gonzalez AL, Medina MJ, Pai R, Thompson TA, Harrison LH, McGee L, Whitney CG; Active Bacterial Core Surveillance Team (2006) Pre- and postvaccination clonal compositions of invasive pneumococcal serotypes for isolates collected in the United States in 1999, 2001, and 2002. J Clin Microbiol 44:999–1017CrossRefPubMedPubMedCentral
19.
go back to reference Farnham AC, Zimmerman CM, Papadouka V, Konty KJ, Zucker JR, Nattanmai GV, Jose S, Rosen JB (2015) Invasive pneumococcal disease following the introduction of 13-valent conjugate vaccine in children in New York City from 2007 to 2012. JAMA Pediatr 169(7):646–652CrossRefPubMed Farnham AC, Zimmerman CM, Papadouka V, Konty KJ, Zucker JR, Nattanmai GV, Jose S, Rosen JB (2015) Invasive pneumococcal disease following the introduction of 13-valent conjugate vaccine in children in New York City from 2007 to 2012. JAMA Pediatr 169(7):646–652CrossRefPubMed
20.
go back to reference Regev-Yochay G, Paran Y, Bishara J, Oren I, Chowers M, Tziba Y, Istomin V, Weinberger M, Miron D, Temper V, Rahav G, Dagan R; IAIPD group (2015) Early impact of PCV7/PCV13 sequential introduction to the national pediatric immunization plan, on adult invasive pneumococcal disease: a nationwide surveillance study. Vaccine 33(9):1135–1142CrossRefPubMed Regev-Yochay G, Paran Y, Bishara J, Oren I, Chowers M, Tziba Y, Istomin V, Weinberger M, Miron D, Temper V, Rahav G, Dagan R; IAIPD group (2015) Early impact of PCV7/PCV13 sequential introduction to the national pediatric immunization plan, on adult invasive pneumococcal disease: a nationwide surveillance study. Vaccine 33(9):1135–1142CrossRefPubMed
21.
go back to reference Rodrigo C, Bewick T, Sheppard C, Greenwood S, Mckeever TM, Trotter CL, Slack M, George R, Lim WS (2015) Impact of infant 13-valent pneumococcal conjugate vaccine on serotypes in adult pneumonia. Eur Respir J 45(6):1632–1641CrossRefPubMed Rodrigo C, Bewick T, Sheppard C, Greenwood S, Mckeever TM, Trotter CL, Slack M, George R, Lim WS (2015) Impact of infant 13-valent pneumococcal conjugate vaccine on serotypes in adult pneumonia. Eur Respir J 45(6):1632–1641CrossRefPubMed
22.
go back to reference Lepoutre A, Varon E, Georges S, Dorléans F, Janoir C, Gutmann L, Lévy-Bruhl D; Microbiologists of Epibac; ORP Networks (2014) Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001–2012. Vaccine 33(2):359–366CrossRefPubMed Lepoutre A, Varon E, Georges S, Dorléans F, Janoir C, Gutmann L, Lévy-Bruhl D; Microbiologists of Epibac; ORP Networks (2014) Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001–2012. Vaccine 33(2):359–366CrossRefPubMed
23.
go back to reference Janoir C, Lepoutre A, Gutmann L, Varon E (2016) Insight into resistance phenotypes ofemergent non 13-valent pneumococcal conjugate vaccine type pneumococci isolatedfrom invasive disease after 13-valent pneumococcal conjugate vaccine implementationin France. Open Forum Infect Dis 3(1):ofw020 Janoir C, Lepoutre A, Gutmann L, Varon E (2016) Insight into resistance phenotypes ofemergent non 13-valent pneumococcal conjugate vaccine type pneumococci isolatedfrom invasive disease after 13-valent pneumococcal conjugate vaccine implementationin France. Open Forum Infect Dis 3(1):ofw020
24.
go back to reference Pai R, Gertz RE, Beall B (2006) Sequential multiplex PCR approach for determining capsular serotypes of Streptococcus pneumoniae isolates. J Clin Microbiol 44:124–131CrossRefPubMedPubMedCentral Pai R, Gertz RE, Beall B (2006) Sequential multiplex PCR approach for determining capsular serotypes of Streptococcus pneumoniae isolates. J Clin Microbiol 44:124–131CrossRefPubMedPubMedCentral
25.
go back to reference Becker-Dreps S, Amaya E, Liu L, Moreno G, Rocha J, Briceño R, Alemán J, Hudgens MG, Woods CW, Weber DJ (2014) Changes in childhood pneumonia and infant mortality rates following introduction of the 13-valent pneumococcal conjugate vaccine in Nicaragua. Pediatr Infect Dis J 33:637–642CrossRefPubMed Becker-Dreps S, Amaya E, Liu L, Moreno G, Rocha J, Briceño R, Alemán J, Hudgens MG, Woods CW, Weber DJ (2014) Changes in childhood pneumonia and infant mortality rates following introduction of the 13-valent pneumococcal conjugate vaccine in Nicaragua. Pediatr Infect Dis J 33:637–642CrossRefPubMed
26.
go back to reference Chacon-Cruz E, Rivas-Landeros RM, Volker-Soberanes ML (2014) Early trends in invasive pneumococcal disease in children following the introduction of 13-valent pneumococcal conjugate vaccine: results from eight years of active surveillance in a Mexican hospital. Ther Adv Vaccines 2:155–158CrossRefPubMedPubMedCentral Chacon-Cruz E, Rivas-Landeros RM, Volker-Soberanes ML (2014) Early trends in invasive pneumococcal disease in children following the introduction of 13-valent pneumococcal conjugate vaccine: results from eight years of active surveillance in a Mexican hospital. Ther Adv Vaccines 2:155–158CrossRefPubMedPubMedCentral
27.
go back to reference García Gabarrot G, López Vega M, Pérez Giffoni G, Hernández S, Cardinal P, Félix V, Gabastou JM, Camou T; Uruguayan SIREVA II Group (2014) Effect of pneumococcal conjugate vaccination in Uruguay, a middle-income country. PLoS One 9:e112337CrossRefPubMedPubMedCentral García Gabarrot G, López Vega M, Pérez Giffoni G, Hernández S, Cardinal P, Félix V, Gabastou JM, Camou T; Uruguayan SIREVA II Group (2014) Effect of pneumococcal conjugate vaccination in Uruguay, a middle-income country. PLoS One 9:e112337CrossRefPubMedPubMedCentral
28.
go back to reference Ben-Shimol S, Greenberg D, Givon-Lavi N, Schlesinger Y, Somekh E, Aviner S, Miron D, Dagan R (2014) Early impact of sequential introduction of 7-valent and 13-valent pneumococcal conjugate vaccine on IPD in Israeli children <5 years: an active prospective nationwide surveillance. Vaccine 32:3452–3459CrossRefPubMed Ben-Shimol S, Greenberg D, Givon-Lavi N, Schlesinger Y, Somekh E, Aviner S, Miron D, Dagan R (2014) Early impact of sequential introduction of 7-valent and 13-valent pneumococcal conjugate vaccine on IPD in Israeli children <5 years: an active prospective nationwide surveillance. Vaccine 32:3452–3459CrossRefPubMed
29.
go back to reference Kempf M, Varon E, Lepoutre A, Gravet A, Baraduc R, Brun M, Chardon H, Cremniter J, Croizé J, Dalmay F, Demachy MC, Fosse T, Grelaud C, Hadou T, Hamdad F, Koeck JL, Luce S, Mermond S, Patry I, Péchinot A, Raymond J, Ros A, Segonds C, Soullié B, Tandé D, Vergnaud M, Vernet-Garnier V, Wallet F, Gutmann L, Ploy MC, Lanotte P (2015) Decline in antibiotic resistance and changes in the serotype distribution of Streptococcus pneumoniae isolates from children with acute otitis media; a 2001–2011 survey by the French Pneumococcal Network. Clin Microbiol Infect 21:35–42 Kempf M, Varon E, Lepoutre A, Gravet A, Baraduc R, Brun M, Chardon H, Cremniter J, Croizé J, Dalmay F, Demachy MC, Fosse T, Grelaud C, Hadou T, Hamdad F, Koeck JL, Luce S, Mermond S, Patry I, Péchinot A, Raymond J, Ros A, Segonds C, Soullié B, Tandé D, Vergnaud M, Vernet-Garnier V, Wallet F, Gutmann L, Ploy MC, Lanotte P (2015) Decline in antibiotic resistance and changes in the serotype distribution of Streptococcus pneumoniae isolates from children with acute otitis media; a 2001–2011 survey by the French Pneumococcal Network. Clin Microbiol Infect 21:35–42
30.
go back to reference Grau I, Ardanuy C, Cubero M, Benitez MA, Liñares J, Pallares R (2016) Declining mortality from adult pneumococcal infections linked to children’s vaccination. J Infect 72:439–449CrossRefPubMed Grau I, Ardanuy C, Cubero M, Benitez MA, Liñares J, Pallares R (2016) Declining mortality from adult pneumococcal infections linked to children’s vaccination. J Infect 72:439–449CrossRefPubMed
31.
go back to reference van der Linden M, Falkenhorst G, Perniciaro S, Imöhl M (2015) Effects of infant pneumococcal conjugate vaccination on serotype distribution in invasive pneumococcal disease among children and adults in Germany. PLoS One 10(7):e0131494CrossRefPubMedPubMedCentral van der Linden M, Falkenhorst G, Perniciaro S, Imöhl M (2015) Effects of infant pneumococcal conjugate vaccination on serotype distribution in invasive pneumococcal disease among children and adults in Germany. PLoS One 10(7):e0131494CrossRefPubMedPubMedCentral
32.
go back to reference van der Linden M, Perniciaro S, Imöhl M (2015) Increase of serotypes 15A and 23B in IPD in Germany in the PCV13 vaccination era. BMC Infect Dis 15:207CrossRefPubMedPubMedCentral van der Linden M, Perniciaro S, Imöhl M (2015) Increase of serotypes 15A and 23B in IPD in Germany in the PCV13 vaccination era. BMC Infect Dis 15:207CrossRefPubMedPubMedCentral
34.
go back to reference Horácio AN, Silva-Costa C, Lopes JP, Ramirez M, Melo-Cristino J; Portuguese Group for the Study of Streptococcal Infections (2016) Serotype 3 remains the leading cause of invasive pneumococcal disease in adults in Portugal (2012–2014) despite continued reductions in other 13-valent conjugate vaccine serotypes. Front Microbiol 7:1616CrossRefPubMedPubMedCentral Horácio AN, Silva-Costa C, Lopes JP, Ramirez M, Melo-Cristino J; Portuguese Group for the Study of Streptococcal Infections (2016) Serotype 3 remains the leading cause of invasive pneumococcal disease in adults in Portugal (2012–2014) despite continued reductions in other 13-valent conjugate vaccine serotypes. Front Microbiol 7:1616CrossRefPubMedPubMedCentral
35.
go back to reference Sá-Leão R, Pinto F, Aguiar S, Nunes S, Carriço JA, Frazão N, Gonçalves-Sousa N, Melo-Cristino J, de Lencastre H, Ramirez M (2011) Analysis of invasiveness of pneumococcal serotypes and clones circulating in Portugal before widespread use of conjugate vaccines reveals heterogeneous behavior of clones expressing the same serotype. J Clin Microbiol 49:1369–1375CrossRefPubMedPubMedCentral Sá-Leão R, Pinto F, Aguiar S, Nunes S, Carriço JA, Frazão N, Gonçalves-Sousa N, Melo-Cristino J, de Lencastre H, Ramirez M (2011) Analysis of invasiveness of pneumococcal serotypes and clones circulating in Portugal before widespread use of conjugate vaccines reveals heterogeneous behavior of clones expressing the same serotype. J Clin Microbiol 49:1369–1375CrossRefPubMedPubMedCentral
36.
go back to reference Varon E, Cohen R, Béchet S, Doit C, Levy C (2015) Invasive disease potential of pneumococci before and after the 13-valent pneumococcal conjugate vaccine implementation in children. Vaccine 33:6178–6185CrossRefPubMed Varon E, Cohen R, Béchet S, Doit C, Levy C (2015) Invasive disease potential of pneumococci before and after the 13-valent pneumococcal conjugate vaccine implementation in children. Vaccine 33:6178–6185CrossRefPubMed
Metadata
Title
Demonstration of the herd effect in adults after the implementation of pneumococcal vaccination with PCV13 in children
Authors
C. Hays
Q. Vermee
A. Agathine
A. Dupuis
E. Varon
C. Poyart
M.-C. Ploy
J. Raymond
and the ORP Ile de France Ouest
Publication date
01-05-2017
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 5/2017
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-016-2868-5

Other articles of this Issue 5/2017

European Journal of Clinical Microbiology & Infectious Diseases 5/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.